Mumbai, India – A total of 135 batches of potassium chloride extended-release capsules are being recalled due to potential health risks that could result in cardiac arrest. The recall was initiated by Glenmark Pharmaceuticals, which pulled back 114 batches, and American Health Packaging, representing BluePoint Laboratories, recalled 21 batches of the same capsules, as reported by the US Food and Drug Administration.
The capsules were recalled because of issues with capsule dissolution, which may lead to elevated potassium levels, also known as hyperkalemia. According to the FDA, hyperkalemia can trigger irregular heartbeats that could potentially lead to a cardiac arrest. Both recalls were issued last week, with Glenmark initiating theirs on Monday and BluePoint following suit the next day.
Despite the recalls, there have been no reports of hyperkalemia or serious adverse events related to the recalled capsules. The capsules are intended for individuals with low potassium levels, also known as hypokalemia, and are sold in bottles of 100 and 500.
Consumers who have purchased the recalled Potassium Chloride Extended-Release Capsules are advised to consult with their healthcare provider before discontinuing use. The FDA has posted the recalled batch numbers for both Glenmark and BluePoint on its website for reference.
It is crucial for consumers to seek medical guidance if they have encountered any issues that may be linked to the usage of this medication. The safety and well-being of patients remain a top priority, and appropriate measures are being taken to address the concerns raised by the flawed medication recall.